 Kasey Couts
Concepts (137)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Melanoma | 16 | 2023 | 620 | 2.810 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2018 | 179 | 1.180 |
Why?
| | Proto-Oncogene Proteins B-raf | 5 | 2018 | 192 | 1.160 |
Why?
| | Skin Neoplasms | 3 | 2022 | 756 | 0.680 |
Why?
| | Septins | 1 | 2018 | 40 | 0.600 |
Why?
| | Melanocytes | 1 | 2012 | 55 | 0.400 |
Why?
| | MicroRNAs | 2 | 2014 | 600 | 0.340 |
Why?
| | Xenograft Model Antitumor Assays | 2 | 2018 | 698 | 0.250 |
Why?
| | Neoplasm Invasiveness | 2 | 2018 | 442 | 0.230 |
Why?
| | Proto-Oncogene Proteins | 2 | 2018 | 608 | 0.230 |
Why?
| | Mutation | 5 | 2022 | 3346 | 0.230 |
Why?
| | MAP Kinase Signaling System | 3 | 2012 | 276 | 0.220 |
Why?
| | Lysophospholipids | 1 | 2023 | 65 | 0.210 |
Why?
| | Myeloid-Derived Suppressor Cells | 1 | 2023 | 56 | 0.200 |
Why?
| | Hematologic Neoplasms | 1 | 2024 | 137 | 0.200 |
Why?
| | Neoplasms, Second Primary | 1 | 2023 | 92 | 0.200 |
Why?
| | HLA-DR Antigens | 1 | 2022 | 219 | 0.190 |
Why?
| | Mucous Membrane | 2 | 2023 | 108 | 0.190 |
Why?
| | Antineoplastic Agents, Immunological | 1 | 2022 | 152 | 0.180 |
Why?
| | Gene Expression Regulation, Neoplastic | 2 | 2018 | 1141 | 0.180 |
Why?
| | Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2020 | 22 | 0.180 |
Why?
| | Antineoplastic Agents | 2 | 2021 | 1879 | 0.170 |
Why?
| | Neoplasms | 2 | 2024 | 2097 | 0.170 |
Why?
| | Signal Transduction | 4 | 2023 | 4513 | 0.170 |
Why?
| | Aniline Compounds | 1 | 2020 | 70 | 0.170 |
Why?
| | Splenectomy | 1 | 2020 | 52 | 0.170 |
Why?
| | Mice, Nude | 2 | 2020 | 630 | 0.170 |
Why?
| | Cell Line, Tumor | 5 | 2018 | 2710 | 0.170 |
Why?
| | Proteomics | 3 | 2014 | 836 | 0.160 |
Why?
| | GTP Phosphohydrolases | 1 | 2018 | 65 | 0.150 |
Why?
| | CD8-Positive T-Lymphocytes | 1 | 2023 | 687 | 0.150 |
Why?
| | Humans | 21 | 2024 | 114686 | 0.150 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 2 | 2009 | 157 | 0.150 |
Why?
| | Gastrointestinal Microbiome | 1 | 2023 | 501 | 0.140 |
Why?
| | Microtubule-Associated Proteins | 1 | 2018 | 174 | 0.140 |
Why?
| | Neurofibromin 1 | 1 | 2017 | 22 | 0.140 |
Why?
| | Armadillo Domain Proteins | 1 | 2017 | 5 | 0.140 |
Why?
| | Phosphoproteins | 2 | 2017 | 298 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-kit | 1 | 2017 | 63 | 0.140 |
Why?
| | RNA Splicing Factors | 1 | 2017 | 49 | 0.140 |
Why?
| | Proto-Oncogene Proteins c-ret | 1 | 2017 | 25 | 0.140 |
Why?
| | Sulfonamides | 1 | 2020 | 445 | 0.140 |
Why?
| | Mitochondrial Proteins | 1 | 2018 | 219 | 0.130 |
Why?
| | Microbiota | 1 | 2023 | 647 | 0.130 |
Why?
| | Protein Isoforms | 1 | 2017 | 338 | 0.130 |
Why?
| | Sequence Analysis, RNA | 1 | 2018 | 385 | 0.130 |
Why?
| | Exome | 1 | 2017 | 200 | 0.130 |
Why?
| | Middle Aged | 6 | 2022 | 26737 | 0.120 |
Why?
| | Peptide Fragments | 1 | 2018 | 666 | 0.120 |
Why?
| | Cell Cycle | 1 | 2006 | 542 | 0.110 |
Why?
| | Protein-Tyrosine Kinases | 1 | 2017 | 395 | 0.110 |
Why?
| | Female | 7 | 2022 | 59507 | 0.110 |
Why?
| | Protein Kinase Inhibitors | 1 | 2018 | 785 | 0.100 |
Why?
| | MAP Kinase Kinase 2 | 1 | 2012 | 27 | 0.100 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2012 | 66 | 0.100 |
Why?
| | Biomarkers, Tumor | 1 | 2017 | 1040 | 0.090 |
Why?
| | Tumor Cells, Cultured | 1 | 2012 | 849 | 0.090 |
Why?
| | RNA Interference | 1 | 2012 | 433 | 0.090 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 535 | 0.090 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 740 | 0.090 |
Why?
| | Male | 6 | 2022 | 55596 | 0.090 |
Why?
| | Immunotherapy | 2 | 2024 | 474 | 0.090 |
Why?
| | Mice | 4 | 2021 | 14869 | 0.080 |
Why?
| | Apoptosis | 1 | 2018 | 2363 | 0.080 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 2 | 2021 | 213 | 0.080 |
Why?
| | Diabetes Mellitus, Type 1 | 1 | 2024 | 3252 | 0.070 |
Why?
| | Receptors, Cell Surface | 1 | 2009 | 355 | 0.070 |
Why?
| | Tumor Suppressor Proteins | 1 | 2009 | 282 | 0.070 |
Why?
| | Nerve Tissue Proteins | 1 | 2009 | 529 | 0.060 |
Why?
| | Cell Proliferation | 1 | 2012 | 2187 | 0.060 |
Why?
| | Animals | 4 | 2021 | 31706 | 0.060 |
Why?
| | High-Throughput Nucleotide Sequencing | 2 | 2017 | 439 | 0.060 |
Why?
| | New York | 1 | 2023 | 106 | 0.050 |
Why?
| | Monitoring, Immunologic | 1 | 2023 | 23 | 0.050 |
Why?
| | Receptors, Lysophosphatidic Acid | 1 | 2023 | 29 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2022 | 3003 | 0.050 |
Why?
| | Aged, 80 and over | 3 | 2020 | 6347 | 0.050 |
Why?
| | Tretinoin | 1 | 2023 | 122 | 0.050 |
Why?
| | Uveal Neoplasms | 1 | 2021 | 8 | 0.050 |
Why?
| | T-Lymphocyte Subsets | 1 | 2024 | 383 | 0.050 |
Why?
| | Tumor Microenvironment | 1 | 2024 | 430 | 0.050 |
Why?
| | Combined Modality Therapy | 1 | 2023 | 1121 | 0.040 |
Why?
| | Receptors, CCR | 1 | 2020 | 7 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2023 | 1167 | 0.040 |
Why?
| | Receptors, Antigen, T-Cell | 1 | 2024 | 615 | 0.040 |
Why?
| | Ultraviolet Rays | 1 | 2022 | 363 | 0.040 |
Why?
| | Alleles | 1 | 2022 | 789 | 0.040 |
Why?
| | Platelet Count | 1 | 2020 | 81 | 0.040 |
Why?
| | Basophils | 1 | 2020 | 64 | 0.040 |
Why?
| | Lymphocyte Subsets | 1 | 2020 | 79 | 0.040 |
Why?
| | Blood Glucose Self-Monitoring | 1 | 2024 | 505 | 0.040 |
Why?
| | Leukocyte Count | 1 | 2020 | 293 | 0.040 |
Why?
| | Postoperative Period | 1 | 2020 | 289 | 0.040 |
Why?
| | Phosphorylation | 2 | 2009 | 1569 | 0.040 |
Why?
| | Pancreaticoduodenectomy | 1 | 2020 | 133 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2020 | 126 | 0.040 |
Why?
| | Dynamins | 1 | 2018 | 29 | 0.040 |
Why?
| | Lymphocytes | 1 | 2020 | 330 | 0.040 |
Why?
| | Genomics | 1 | 2022 | 635 | 0.040 |
Why?
| | Apoptosis Regulatory Proteins | 1 | 2018 | 171 | 0.040 |
Why?
| | Monocytes | 1 | 2020 | 504 | 0.030 |
Why?
| | Octamer Transcription Factors | 1 | 2006 | 2 | 0.030 |
Why?
| | Peptide Elongation Factor 2 | 1 | 2006 | 3 | 0.030 |
Why?
| | Nuclear Matrix-Associated Proteins | 1 | 2006 | 5 | 0.030 |
Why?
| | Survival Analysis | 1 | 2020 | 1211 | 0.030 |
Why?
| | Electrophoresis, Gel, Two-Dimensional | 1 | 2006 | 100 | 0.030 |
Why?
| | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2006 | 134 | 0.030 |
Why?
| | Gene Rearrangement | 1 | 2017 | 135 | 0.030 |
Why?
| | Aged | 3 | 2020 | 19074 | 0.030 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 1355 | 0.030 |
Why?
| | Blood Glucose | 1 | 2024 | 1828 | 0.030 |
Why?
| | HeLa Cells | 1 | 2006 | 562 | 0.030 |
Why?
| | Enzyme Activation | 1 | 2006 | 785 | 0.030 |
Why?
| | Isotope Labeling | 1 | 2014 | 69 | 0.030 |
Why?
| | 3' Untranslated Regions | 1 | 2014 | 129 | 0.030 |
Why?
| | RNA-Binding Proteins | 1 | 2006 | 345 | 0.030 |
Why?
| | Adult | 3 | 2020 | 30550 | 0.030 |
Why?
| | Amino Acid Sequence | 1 | 2006 | 1982 | 0.030 |
Why?
| | Molecular Sequence Data | 1 | 2006 | 2785 | 0.020 |
Why?
| | Kinetics | 1 | 2014 | 1551 | 0.020 |
Why?
| | Biomarkers | 1 | 2020 | 3408 | 0.020 |
Why?
| | Group II Chaperonins | 1 | 2009 | 2 | 0.020 |
Why?
| | DNA-Binding Proteins | 1 | 2006 | 1314 | 0.020 |
Why?
| | Prognosis | 1 | 2017 | 3329 | 0.020 |
Why?
| | Spheroids, Cellular | 1 | 2009 | 56 | 0.020 |
Why?
| | Melanoma, Experimental | 1 | 2009 | 89 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2017 | 4411 | 0.020 |
Why?
| | Substrate Specificity | 1 | 2009 | 352 | 0.020 |
Why?
| | Molecular Chaperones | 1 | 2009 | 157 | 0.020 |
Why?
| | Algorithms | 1 | 2014 | 1469 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2014 | 2764 | 0.020 |
Why?
| | RNA, Messenger | 1 | 2014 | 2553 | 0.020 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2009 | 398 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2009 | 633 | 0.020 |
Why?
| | Cell Movement | 1 | 2009 | 869 | 0.020 |
Why?
| | Time Factors | 1 | 2014 | 6115 | 0.010 |
Why?
| | Retrospective Studies | 1 | 2020 | 12550 | 0.010 |
Why?
|
|
Couts's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|